• 1
    Materson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens. 1995;8:189192.
  • 2
    Materson BJ, Kessler WB, Alderman MH, et al. A multicenter, randomized, double-blind dose-response evaluation of step-2 guanfacine versus placebo in mild to moderate hypertension. Am J Cardiol. 1986;57:32E37E.
  • 3
    Rahn KH, Barenbrock M, Hausberg M. The sympathetic nervous system in the pathogenesis of hypertension. J Hypertens Suppl. 1999;17:S11S14.
  • 4
    Frohlich ED. Methyldopa. Mechanisms and treatment 25 years later. Arch Intern Med. 1980;140:954959.
  • 5
    Fenton C, Keating G, Lyseng-Williamson, et al. Moxonidine: a review of its use in essential hypertension. Drugs. 2006;66:477496.
  • 6
    Reid JL. Rilmenidine: a clinical overview. Am J Hypertens. 2000;13:106S111S.
  • 7
    van Zwieten PA. The renaissance of centrally acting antihypertensive drugs. J Hypertens Suppl. 1999;17:S15S21.
  • 8
    Goldberg M, Gehr M. Effects of alpha-2 agonists on renal function in hypertensive humans. J Cardiovasc Pharmacol. 1985;7(suppl 8):S34S37.
  • 9
    Dollery CT. Advantages and disadvantages of alpha 2-adrenoceptor agonists for systemic hypertension. Am J Cardiol. 1988;61:1D5D.
  • 10
    Mohammed S, Fasola AF, Privitera PJ, et al. Effect of methyldopa on plasma renin activity in man. Circ Res. 1969;25:543548.
  • 11
    Foxworth JW, Reisz GR, Pyszczynski DR, et al. Oral clonidine in patients with asthma: no significant effect on airway reactivity. Eur J Clin Pharmacol. 1995;48:1922.
  • 12
    Dorman T, Clarkson K, Rosenfeld BA, et al. Effects of clonidine on prolonged postoperative sympathetic response. Crit Care Med. 1997;25:11471152.
  • 13
    Sica DA, Grubbs R. Transdermal clonidine: therapeutic considerations. J Clin Hypertens (Greenwich). 2005;7:558562.
  • 14
    Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 15
    Khedun S, Maharaj B, Moodley J. Effects of antihypertensive drugs on the unborn child. What is known, and how should this influence prescribing? Paediatr Drugs. 2000;2:419436.
  • 16
    Neerhof MG. Pregnancy in the chronically hypertensive patient. Clin Perinatol. 1997;24:391406.
  • 17
    Houston MC. Treatment of hypertensive emergencies and urgencies with oral clonidine loading and titration. Arch Intern Med. 1986;146:586589.
  • 18
    MacGregor TR, Matzek KM, Keirns JJ, et al. Pharmacokinetics of transdermally delivered clonidine. Clin Pharmacol Ther. 1985;38:278284.
  • 19
    Hopkins K, Aarons L, Rowland M. Absorption of clonidine from a transdermal therapeutic system when applied to different body sites. In: WeberMA, MathiasCJ, eds. Mild Hypertension. Darmstadt, Germany; Steinkopf Verlag; 1984:143.
  • 20
    Meacham RH, Emmett M, Kyriakopoulos AA, et al. Disposition of 14C-guanabenz in patients with essential hypertension. Clin Pharmacol Ther. 1980;27:4452.
  • 21
    Capuzzi DM, Cevallos WH. Inhibition of hepatic cholesterol and triglyceride synthesis by guanabenz acetate. J Cardiovasc Pharmacol. 1984;6(suppl 5):S847S852.
  • 22
    Oster JR, Epstein M. Use of centrally acting sympatholytic agents in the management of hypertension. Arch Intern Med. 1991;151:16381644.
  • 23
    Cornish LA. Guanfacine hydrochloride: a centrally acting antihypertensive agent. Clin Pharm. 1988;7:187197.
  • 24
    Kirch W, Hutt HJ, Planitz V. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin Pharmacokinet. 1988;15:245253.
  • 25
    Cohn JN, Pfeffer MA, Rouleau J, et al. Adverse mortality effect of central sympathetic inhibition with sustained release moxonidine in patients with heart failure (MOXCON). Eur J Heart Fail. 2003;5:659667.
  • 26
    Zannad F, Aliot E, Florentin J, et al. Hemodynamic and electrophysiologic effects of a new alpha 2-adrenoceptor agonist, rilmenidine, for systemic hypertension. Am J Cardiol. 1988;61:67D71D.
  • 27
    Buchman AL, Fryer J, Wallin A, et al. Clonidine reduces diarrhea and sodium loss in patients with proximal jejunostomy: a controlled study. JPEN J Parenter Enteral Nutr. 2006;30:487491.
  • 28
    Lenaerts A, Codden T, Meunier JC, et al. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. Hepatology. 2006;44:844849.
  • 29
    Azevedo ER, Newton GE, Parker JD. Cardiac and systemic sympathetic activity in response to clonidine in human heart failure. J Am Coll Cardiol. 1999;33:186191.
  • 30
    Simpson CS, Ghali WA, Sanfilippo AJ, et al. Clinical assessment of clonidine in the treatment of new-onset rapid atrial fibrillation: a prospective, randomized clinical trial. Am Heart J. 2001;142:E3.
  • 31
    Bravo EL, Tarazi RC, Fouad FM, et al. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med. 1981;305:623626.
  • 32
    van Zwieten PA, Thoolen MJ, Timmermans PB. The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine. Hypertension. 1984;6:II28II33.
  • 33
    Webster J, Koch HF. Aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol. 1996;27:S49S54.
  • 34
    Watson GE, Pearson SK, Bowen WH. The effect of chronic clonidine administration on salivary glands and caries in the rat. Caries Res. 2000;34:194200.
  • 35
    Carstairs KC, Breckenridge A, Dollery CT, et al. Incidence of a positive direct coombs test in patients on alpha-methyldopa. Lancet. 1966;2:133135.
  • 36
    Byrd BF III, Collins HW, Primm RK. Risk factors for severe bradycardia during oral clonidine therapy for hypertension. Arch Intern Med. 1988;148:729733.
  • 37
    Hansson L, Hunyor SN, Julius S, et al. Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management. Am Heart J. 1973;85:605610.
  • 38
    Domino LE, Domino SE, Stockstill MS. Relationship between plasma concentrations of clonidine and mean arterial pressure during an accidental clonidine overdose. Br J Clin Pharmacol. 1986;21:7174.
  • 39
    Ito MK, O'Connor DT. Skin pretreatment and the use of transdermal clonidine. Am J Med. 1991;91:42S49S.
  • 40
    Tom GR, Premer R. Hydrocortisone cream in clonidine patch dermatitis. Ann Pharmacother. 1994;28:889890.
  • 41
    McChesney JA. Preventing the contact dermatitis caused by a transdermal clonidine patch [letter]. West J Med. 1991;154:736.